SLC5A2 and acute kidney injury: For patients with CKD, each 1000 patient-years of treatment with an SGLT-2 inhibitor was estimated to prevent 18 first kidney disease progression and 5 serious AKI events, 6 HF hospitalizations, 3 cardiovascular deaths, and 1 MI, and cause 1 additional amputation and 0.3 ketoacidosis events.